

Topical Collection

Advance in Nanoparticles as Vaccine Adjuvants

Message from the Collection Editors

Remarkable efforts have been made to develop new and improved vaccines attending antigen's nature and immune mechanisms involved. To obtain an appropriate humoral and cell-mediated immunity, risk-free and effective vaccines are needed against infectious diseases and tumoral processes. In the last years, nanoparticles have gained much interest in new vaccines generation since they can protect the antigen targets from premature proteolytic degradation, lead to a homogeneous uptake of antigens by immune cells, and facilitating their processing and presentation. Nanoparticles composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. This special issue aims to collect recent original research and reviews on nanoparticulate-loaded vaccines attain their nature, formulation, delivery, their safe and efficacy, and induced immune responses to accomplish efficient and long-lasting protection against infectious diseases and tumors. I look forward to receiving your contributions.

Collection Editors

Dr. Eduardo Gomez-Casado

Department of Biotechnology, INIA-CSIC, 28040 Madrid, Spain

Dr. Sohrab Ahmadvand

Faculty of Veterinary Medicine, Ludwig Maximilian University of Munich, 80539 München, Germany



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/94187

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).